On the other hand, saracatinib, another molecule recently noted for its antifibrotic potential by influencing TGF-β, though not yet investigated in post-COVID-19 fibrosis, has demonstrated an increased potential in intercepting profibrotic inflammatory cascades and organizing the extracellular matrix [107]. The gene discussed is TGFB1; the disease is COVID-19.